Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Gallium Ga 68-labeled PSMA-11 PET/CT in Diagnosing Participants with Biochemical Recurrent Prostate Cancer

Trial Status: closed to accrual

This phase II trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment (biochemical recurrent). Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET/CT, may help find the presence of prostate cancer.